Condition

Metastatic Uveal Melanoma clinical trials and research

• 11Clinical trials
• 2NIH research projects
• 5Countries

Newest Metastatic Uveal Melanoma clinical trials

All recruiting trials (11)

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• Dual-target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

  This study tests a donor-derived CAR-NK cell therapy that targets CSPG4 or GD2 in adults with unresectable or metastatic melanoma after standard treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07627698

• Melphalan liver perfusion followed by tebentafusp for metastatic uveal melanoma

  This Phase 2 trial tests whether melphalan delivered to the liver by percutaneous hepatic perfusion followed by tebentafusp helps people with HLA-A*02:01-positive metastatic uveal melanoma confined to the liver.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07276386

• NBM-BMX for adults with metastatic uveal melanoma — dose-finding and safety

  This study will test whether taking the oral drug NBM-BMX twice daily is safe, how the body handles it, and whether it can slow or shrink tumors in adults with metastatic uveal melanoma while finding the best dose.

  Recruiting at 3 sites Phase 1/2 Novelwise Pharmaceutical Corporation · Scottsdale, Arizona and 2 other locations · NCT07136181

• Adding IL-2 to tebentafusp to overcome resistance in uveal melanoma

  This trial tests whether giving interleukin‑2 (IL‑2) together with tebentafusp can help people with HLA‑A*02:01 metastatic uveal melanoma who progressed on tebentafusp.

  Recruiting Phase 1/2 St Vincent's Hospital, Sydney · Sydney, New South Wales and 1 other locations · NCT07063875

• Combining Tebentafusp with Radioembolization for Liver Metastases from Uveal Melanoma

  This study is testing whether combining a new drug called Tebentafusp with a specific type of radiation treatment can help people with liver cancer that started from uveal melanoma.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06627244

• Tebentafusp plus liver-directed therapy for metastatic uveal melanoma

  This trial tests whether combining tebentafusp with liver-directed treatments helps HLA-A*02:01-positive adults with metastatic uveal melanoma keep their liver tumors from growing.

  Recruiting Phase 1/2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT06626516

• Investigating RP2 and Nivolumab for Metastatic Uveal Melanoma

  This study is testing whether a new treatment combining RP2 with nivolumab can help adults with metastatic uveal melanoma feel better compared to the standard treatment of nivolumab and ipilimumab.

  Recruiting at 33 sites Phase 2/3 Replimune, Inc. · Scottsdale, Arizona and 32 other locations · NCT06581406

• Combining Cemiplimab and Ziv-Aflibercept for Metastatic Uveal Melanoma

  This study is testing if the combination of Cemiplimab and Ziv-Aflibercept can help shrink tumors or stop their growth in people with metastatic uveal melanoma who have already tried other treatments.

  Recruiting at 4 sites Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Los Angeles, California and 3 other locations · NCT06121180

• Evaluating lifileucel in patients with advanced uveal melanoma and certain sarcomas

  This study is testing a new treatment called lifileucel to see if it can help people with advanced uveal melanoma and certain types of sarcomas feel better.

  Recruiting at 2 sites Phase 1 Memorial Sloan Kettering Cancer Center · Harrison, New York and 1 other locations · NCT05607095

• Evaluating IDE196 for patients with specific solid tumors

  This study is testing a new treatment called IDE196 for people with specific solid tumors that have certain genetic changes to see if it can help shrink their tumors and how safe it is.

  Recruiting at 7 sites Phase 1/2 IDEAYA Biosciences · Los Angeles, California and 14 other locations · NCT03947385

NIH-funded research (2)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Dual mRNA therapeutics aimed at liver metastasis from uveal melanoma

  A new approach uses two mRNA-based therapies designed to target liver metastases in adults with uveal melanoma.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11388819

• Investigating a new treatment for uveal melanoma using a specific drug.

  This study is testing a new drug called 64B to see if it can help treat advanced eye cancer, specifically metastatic and high-risk uveal melanoma, by working alongside other treatments to slow down tumor growth and improve survival, making it a hopeful option for patients facing this condition.

  NIH research Oncospherix, INC. · Atlanta, United States · NIH-10817841

Related topics

Quick answers

How many Metastatic Uveal Melanoma clinical trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in United States (9 trials), Australia (3 trials), Canada (1 trial), China (1 trial), United Kingdom (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 6, Phase 2: 3, Phase 1: 1, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →